• Medical cannabis reform in Brazil is slowly taking shape
• Challenges include the cost of medical cannabis products and medical cannabis patients living close to available access
• With its background in connected devices, big data, and technology, RYAH appears well qualified to provide insight on medical cannabis around the world

While the cannabis world’s attention is often focused on what’s happening in North America, activity in Latin America may be making significant progress. For example, a recent blog post (https://ibn.fm/t36SM) from RYAH Group (CSE: RYAH) states that “Brazil, one of the region’s largest markets, is quietly, if incrementally, making advances toward a powerful medical cannabis program.” The blog, titled “Past, Present, and Future: Medical Cannabis in Brazil,” notes that “medical cannabis in Brazil may face some steep political hurdles, but the waves of reform are slowly making it possible for more patients to access more medicine.” The largest South American country both in size and population, Brazil boasts a GDP per capita of $15,388. “At the time of writing, there are several different estimates about the number of people currently authorized as medical cannabis patients,” the article continued. “For example, there may be 14,500 or more patients served by the country’s only legal patient association and 20,000 more citizens approved to import products into the country.” Observing that it’s unclear if there is any overlap in those numbers, the article explains three ways medical cannabis patients can obtain cannabis in the country: through a pharmacy, patient association, and imports. “For most patients in Brazil, medical cannabis products are far too expensive, and few people live close enough to the only patient association, ABRACE, to access more affordable options,” the blog explains. “Furthermore, unlike the medicinal options available in other countries, the Brazilian program primarily focuses on high-CBD, low-THC options.” While the country has faced challenges, RYAH notes that Brazil seems poised at the top of a crest. “Slow legislative reforms have been building for years, gradually offering patients more options for medical cannabis,” the article states. “But the country isn’t quite there yet. A few additional pieces need to fall into place to finally open the flood gates, including legalizing the local cultivation of medical cannabis and hemp. With the current political climate in the country pushing against the tide, it remains uncertain when this legislation will finally come to pass.” With its background in connected devices, big data, and technology, RYAH appears well qualified to provide insight on medical cannabis around the world. The company was granted the first patent granted in AI data analytics in plant-based medicine and owns one of the largest plant-based medicine databases in the world with more than 200,000 registered users. In addition, the company’s multiple IoT device portfolio is designed to capture a broader patient demographic and the clinical trial market. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• Recent DSA study reported that the direct-selling channel generated $40.1 billion in retail sales in 2020, an increase of 13.9% from the previous year
• Study shows that direct-selling companies adapted quickly to a changing world by empowering their independent sellers
• SHRG’s The Happy Co. launched in February 2021 and offers functional beverages, capsules, patches and creams

Direct sales grew almost 14% last year in the United States, according to the most recent Direct Selling Association report (https://ibn.fm/T611K). Sharing Services Global (OTCQB: SHRG), a publicly traded company specializing in the direct-sales sector, stands to benefit from this trend, especially as the company focuses on innovating its direct-sales efforts, including the rebranding of its subsidiary operating in this space. The DSA study reported that the direct-selling channel generated $40.1 billion in retail sales in 2020, an increase of 13.9% from the previous year. The study also noted that the number of people selling products or services using the direct-selling model also increased, posting 13.2% growth, with 7.7 million U.S. entrepreneurs working part-time or full-time. Numbers also show that demand for direct-selling products is growing,with 41.6 million preferred customers and discount buyers purchasing through the direct-sales channel in 2020. “U.S. Direct Selling Association (‘DSA’), the national trade association for companies that offer entrepreneurial opportunities to individuals who choose to sell products and services direct to customers, released its Direct Selling Growth and Outlook Survey results for 2020 today, showing double-digit growth in retail sales, direct sellers, and customers of the channel,” reported a recent DSA article. “Growth & Outlook is DSA’s annual survey that reports on the size and scope of direct selling in the U.S. and is audited by Nathan Associates, a third-party international economic consulting firm.” The article went on to quote DSA president Joseph N. Mariano, who stated that “America is forever changing, no more so than during the last year. Direct sellers have proven themselves time and again to be nimble microentrepreneurs, willing and able to serve their customers and communities within a changing environment. “The direct selling companies also adapted quickly to a world with changing needs by empowering their independent sellers with the tools to serve their customers and fellow sellers – innovative technology, updated health and safety policies, and second-to-none business support,” he continued. “During this time of uncertainty, Direct Selling Association and its members also worked to ensure that customers and salespeople alike can rely upon the highest level of business ethics.  The results are clear — a record-breaking year and an unequivocal demonstration that direct selling is dedicated to serving America.” Paul Bourquin, principal at Nathan Associates, said, “Since 1995, Nathan Associates has been proud to work with the DSA analyzing the Growth & Outlook Survey data and conducting extensive secondary research to develop industry-wide estimates for the U.S. direct selling industry. As a third-party international economic consulting firm, we deliver methodologically sound industry wide estimates to help DSA serve as a trusted source of data on the full direct selling channel in the U.S.” SHRG’s The Happy Co. launched in February 2021 and offers functional beverages, capsules, patches and creams that elevate mood, boost energy, reduce stress, enhance sleep, increase muscles, minimize fat and tighten skin, and make users look, feel and perform like a younger person. The products are nootropics, or nutraceutical formulations derived from food sources that provide health benefits above and beyond basic nutritional value. Sharing Services Global Corporation is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Home Health and Diabetes Care Program helps suppliers present their offerings to buyers from major US chains actively searching for new products to sell
• InnerScope raised buyers’ interest as the only company presenting direct-to-consumer hearing products; scheduled 50 one-on-one meetings with corporate buyers from major US retailers
• Company is poised to forge key strategic relationships to build robust distribution network with industry-leading partners

InnerScope Hearing Technologies (OTC: INND), an emerging disruptive leader in the direct-to-consumer hearing technology space, participates in the virtual Home Health & Diabetes Care Program — an event that connects sellers and corporate buyers (https://ibn.fm/XCtPR). With its unique technology that customers can use from the comfort of their homes, InnerScope is the only company from the hearing device and hearing healthcare category to present at the event. The Company is able to showcase its broad range of hearing aids and accompanying products to corporate buyers from the home health care sector, but also to pitch its offering to buyers from the diabetes healthcare space since hearing impairment is often associated with this disease—hearing loss is twice as frequent in diabetes patients as it is in those who don’t suffer from it (https://ibn.fm/ApqHt). The event running from Sept. 20–23, 2021, is intended to drive business opportunities for presenting companies by ensuring they get in front of the right people at the right time to make a sale and build a lasting business relationship. Acting as a bridge between buyers and suppliers, the virtual Home Health and Diabetes Care Program features some of the biggest names in the healthcare consumer products category. The Program provides InnerScope with a unique opportunity to demonstrate its unmatched direct-to-consumer hearing devices and hearing health products to 50 corporate buyers from some of the largest US retailers, including industry heavyweights such as CVS and Kroger Costco, H-E-B, QVC, AmerisourceBergen, McKesson, and more. During the event, the Company aims to demonstrate its broad range of hearing products, including Bluetooth app-controlled self-adjusting hearing aids and personal sound amplifiers products, as well as doctor-formulated dietary hearing and tinnitus supplements, and assorted ear and hearing health-related products. In over 50 one-on-one meetings slated for this virtual event, InnerScope hopes to forge important strategic relationships building its retail and wholesale distribution network among industry-leading partners. As a company empowering consumers to take control of their hearing healthcare, InnerScope aims to position itself as a go-to provider for all things hearing-related. Unmatched within the direct-to-consumer hearing aid products, the Company is able to showcase its disruptive innovative products while highlighting its unique selling proposition and revealing its distinctive journey towards becoming a leading direct-to-consumer disruptor within the hearing device space. For more information, visit the company’s website at www.INND.com and the company’s e-commerce website: www.MyHearIQ.com. NOTE TO INVESTORS: The latest news and updates relating to INND are available in the company’s newsroom at https://ibn.fm/INND

• StorEn issued ANYSeed a convertible note in 2019; the fund recently converted the note into equity
• ANYSeed supports science and technology-based, early-stage ventures located in downstate New York
• Focused on offering innovative battery storage, StorEn Technologies is leading way in the development of evolutionary vanadium flow batteries

StorEn Technologies, a developer of evolutionary vanadium flow batteries with a disruptive patent-pending, all-vanadium flow battery technology, has announced that Accelerate New York Seed Fund (ANYSeed) has become a shareholder (https://ibn.fm/vJewK). “Over three years ago, in March of 2019, we raised funds from ANYSeed and issued them a convertible note after receiving the financing,” StorEn announced. “If you’re not familiar with how convertible notes work, they are a popular fundraising instrument, a hybrid of debt and equity. They are structured as loans with the option of converting to equity, as opposed to requesting the repayment of the principal plus accrued interest. “We’re so grateful to ANYSeed for converting their note into equity,” the announcement continued. “Thank you for supporting our enduring progress in the path to volume manufacturing. . . . With the help of all our shareholders, like ANYSeed, we are striving to make StorEn a success.” In partnership with Empire State Development, the Accelerate NY Seed Fund supports science and technology-based, early-stage ventures located in downstate New York (https://ibn.fm/OD9ps). The fund’s mission is to facilitate the transition from laboratory research and ideas into products, processes and services that deliver a financial return to investors. The fund considers projects in the biopharma, materials, tech, med tech, healthcare and energy sectors, with a strong preference for research institution affiliation and intellectual property strength. With its strong tie to Stony Brook University in New York, StorEn Technologies fits the bill perfectly. Focused on offering innovative battery storage for the 21st century, StorEn Technologies is leading the way forward in the development of evolutionary vanadium flow batteries. The battery pioneer is currently in the middle of a Reg A offering, creating a unique opportunity for investors interested in the future of battery storage. StorEn is currently in the process of a RegA offering with four different investment tiers; each tier offers a different discount and reward (https://ibn.fm/E4IcJ). With a proprietary product that answers the call for long-lasting, 100% recyclable, safe and affordable energy storage, StorEn and its disruptive, patent-pending, all-vanadium flow battery technology for energy storage holds real promise in a growing market. The company has developed evolutionary vanadium flow batteries. Incubated at the Clean Energy Business Incubator Program (“CEBIP”) within Stony Brook University in New York, the company is building upon the strengths of vanadium flow batteries to revolutionize the world of residential and industrial energy storage. In part, StorEn’s technology has enhanced the electrical efficiency of the stack and energy density of the electrolyte and module, ultimately reducing costs and improving performance. The company produces products with a battery life of 25 years and more than 15K cycles. That company takes pride in offering batteries that meet consumers demand for efficient, durable and cost-effective energy storage, enabling self-consumption of self-produced electricity and the transition toward a carbon-free economy. For more information, visit the company’s website at www.StorEn.tech. NOTE TO INVESTORS: The latest news and updates relating to StorEn Technologies are available in the company’s newsroom at https://ibn.fm/StorEn

• Nemaura Medical is a medical technology company focused on developing non-invasive wearable diagnostic devices
• The company recently revealed its participation at the annual H.C. Wainwright Global Investment Conference, held between September 13-15, 2021
• Through its sugarBEAT flagship product, Nemaura has sought to capitalize on the expanding Type 2 Diabetes market, expected to reach an annual value of $59 billion by 2025

Nemaura Medical (NASDAQ: NMRD) is a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs; the company’s flagship product, the sugarBEAT(R), is a wearable, non-invasive and flexible Continuous Glucose Monitor designed to help people with diabetes and prediabetes manage their glucose levels. Nemaura Medical’s management recently revealed their attendance at the 23rd Annual H.C. Wainwright Global Investment Conference, held in an entirely digital forum between September 13-15, 2021 (https://ibn.fm/1OiBy). Initially founded in 1868, H.C. Wainwright is a U.S.-based investment bank offering leading-edge investment banking, corporate finance, and strategic advisory services to public and private growth companies across multiple sectors and regions. The 23rd Annual H.C. Wainwright Global Investment Conference (https://ibn.fm/x6vUI) featured over 850 corporates in attendance, distributed across six distinctive sector tracks, namely – healthcare & life sciences; metals & mining; cryptocurrency, blockchain, & fintech; cleantech; technology, media & telecommunications; as well as shipping & maritime. In addition, the conference featured some of the industry’s leading keynote speakers, one-on-one investor meetings, and networking opportunities with attendees. H.C. Wainwright’s annual investment conference routinely attracts some of North America’s largest institutional investors, private equity firms, and venture capitalists seeking new investment opportunities. Over 420 million people globally are currently living with diabetes, with prediabetic cases totalling almost three times that number. In the US alone, over $760 billion was spent on diabetes-related health care expenditures during 2019, equating to an average annual spend upwards of $9,000 per diabetic patient compared to approximately $1,600 for a healthy individual (https://ibn.fm/Fzjhi). Combining clinical research with patient-friendly technology and through its sugarBEAT product, Nemaura Medical seeks to provide a non-invasive, affordable, and flexible method of blood glucose tracking for improved diabetes management. NMRD has positioned itself at the intersection of the global Type 2 diabetes market, which is expected to reach an annual value of nearly $59 billion by 2025. Moreover, the product also allows the company to participate in the $50-plus billion prediabetic market and the wearable health-tech sector for weight loss and wellness applications, which is forecast to hit $60 billion by 2023. For more information, visit the company’s website at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• WHO survey reports that mental health services in 93% of countries around the world have been disrupted or halted as a result of COVID-19
• People with pre-existing mental, neurological or substance-use disorders are more vulnerable to SARS-CoV-2 infection
• Cybin is on a mission to revolutionize mental healthcare

A World Health Organization (“WHO”) survey covering 130 countries is calling attention to the fact that today’s demand for mental health, which has been rocked by the COVID-19 pandemic, is only increasing (https://ibn.fm/hzmXq). Cybin (NEO: CYBN) (NYSE American: CYBN) is focused on meeting that need and is committed to finding even more effective ways to help those struggling with mental health issues. “The COVID-19 pandemic has disrupted or halted critical mental health services in 93% of countries worldwide while the demand for mental health is increasing, according to a new WHO survey,” a WHO news release reported. “The survey of 130 countries provides the first global data showing the devastating impact of COVID-19 on access to mental health services and underscores the urgent need for increased funding.” The release goes on to note that the underfunding of mental health issues is nothing new. “Prior to the pandemic, countries were spending less than 2% of their national health budgets on mental health, and struggling to meet their populations’ needs,” the release pointed out. “And the pandemic is increasing demand for mental health services. Bereavement, isolation, loss of income and fear are triggering mental health conditions or exacerbating existing ones. “Many people may be facing increased levels of alcohol and drug use, insomnia, and anxiety. Meanwhile, COVID-19 itself can lead to neurological and mental complications, such as delirium, agitation, and stroke. People with pre-existing mental, neurological or substance use disorders are also more vulnerable to SARS-CoV-2 infection — they may stand a higher risk of severe outcomes and even death.” The report quotes the director-general of WHO, Dr. Tedros Adhanom Ghebreyesus. “Good mental health is absolutely fundamental to overall health and well-being. COVID-19 has interrupted essential mental health services around the world just when they’re needed most. World leaders must move fast and decisively to invest more in life-saving mental health programs — during the pandemic and beyond.” The survey only underscores the work that Cybin is doing. This game-changing company is keenly aware that more than 700 million people around the world are impacted with some sort of mental illness, addiction or eating disorder, and the company is on a mission to revolutionize mental healthcare. The innovative organization is focused on leveraging its expertise in the psychedelic therapeutic space to deliver proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. “We are focused on addressing the mental health crisis and transforming the treatment landscape,” the company’s website states. “To do that, we are combining technology and our scientific expertise to pair novel psychedelic molecules with controllable drug delivery systems, aimed at improving outcomes for patients.” For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• StraightUp Resources is a mineral property acquisition and exploration company currently focused on potential production targets in Ontario, Canada’s historic Red Lake Mining District
• StraightUp has options to four flagship properties that together comprise over 20,000 hectares (about 50,000 acres) in a region that has produced more than 30 million ounces of gold historically
• The company announced this month that it has completed a high-resolution heli-borne magnetic survey (“MAG”) on its largest project that will help the company decide where potential gold mineralization worth further exploration may lie
• The company’s efforts to fund its exploration work include a recently announced private placement offering and an initial financing tranche closing that raised C$301,100

Mineral explorer and acquisition company StraightUp Resources (CSE: ST) is making inroads on the evaluation of potential yields from flagship properties it has acquired options to in the well-known rich gold resource district within Ontario, Canada. StraightUp announced earlier this month that it had completed a high-resolution heli-borne magnetic survey (“MAG”) on the RLX North and RLX South properties that comprise the company’s largest area of operation currently — claims covering over 10,000 hectares (about 25,000 acres). The MAG survey consists of 2,985 line-km at 50-meter line intervals covering the entire property and the results will be used to help determine areas of potential gold mineralization and high-merit areas worthy of further exploration. “It is exciting to see how the adoption of technology has led to such advanced interpretation and with computer modelling, revolutionization of the industry,” StraightUp President and CEO Mark Brezer stated in a news release announcing the project’s status (https://ibn.fm/M3M5Z). “These projects are in the heart of the Red Lake Mining District, an area that is seeing a resurgence of gold bearing deposits that were overlooked in the past. RLX North and South almost completely surround Great Bear Resources Sobel Project and with our accumulated data from the region and upcoming MAG results, we can better pin-point future drill programs.” The Red Lake district is renowned for over 30 million ounces of historic gold production, and the RLX projects are situated near the Red Lake Mine complex that is the district’s largest gold deposit with estimated reserves of 3.23 million ounces as of a 2019 report (https://ibn.fm/qQtLi). The company regards the contact between the metavolcanic packages of north and south RLX properties as “highly prospective” for economic deposits of gold, or deposits that are formed in such a way that they can be mined out of economic interests. Most of the ore production that has taken place in the district historically has come from within a few hundred meters of the contact point, according to the company. The RLX properties are joined by other neighboring projects StraightUp has optioned, including the 6,600-hectare (16,308-acre) Ferdinand Gold Property, the 2,000-hectare (4,942-acre) Belanger property and the 1,944-hectare (4,803-acre) Bear Head Gold Project, which extend into a neighboring greenstone belt. As StraightUp evaluates the prospects of the properties, it continues to acquire financing for the projects. Concurrent with the announcement of completing the RLX MAG survey, the company announced a non-brokered financing to raise up to C$2 million through a private placement offering and the close of the first tranche of the financing, raising C$301,100 by issuing 1.5 million common shares and 752,750 warrants. The private placement offers one common share at a price of C$0.20 and one-half of a transferable common share purchase warrant, which can be used to buy an additional common share at a price of C$0.30 per whole warrant. The net proceeds will be used to fund upcoming exploration projects and other property expenditures. In June, the company received preliminary MAG survey results from its Ferdinand Gold Project and began ground work exploration there in August (https://ibn.fm/28CmC). In June the company also filed an NI 43-101 compliant technical report that recommends further exploration on the Belanger Property (https://ibn.fm/2de7C). For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to ST are available in the company’s newsroom at https://ibn.fm/STR

• Delic has positioned itself as a leading psychedelic wellness platform, with businesses spanning all corners within the sector
• Delic’s latest announced acquisition will make it the largest chain of operating psychedelic wellness clinics in the US
• The psychedelic wellness sector has enjoyed robust growth as of late, following the FDA’s move towards granting psilocybin “breakthrough therapy” status in 2018
• Denver and Oakland have been among the first US cities to decriminalize the use of psilocybin mushrooms with California currently studying whether to follow suit
• The psychedelic drugs market is expected to reach a size of $10.75 billion by 2027

When Michael Pollard embarked on writing his seminal book, How to Change Your Mind in 2018, the psychedelic wellness industry was a far different world to what we know today (https://ibn.fm/SiWdt). Although the psychedelic industry boasts a long history in America dating back to the 1950s, it’s only in the last few years that scientific research into the world of psychedelics and its related compounds has uncovered their potential to relieve a wide array of mental suffering, including depression, anxiety, and addiction. Delic Holdings (CSE: DELC) (OTCQB: DELCF) has sought to capitalize on the ongoing transformation within the sector, positioning itself as the leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation. Originally formed in 2019 to address the growing interest within the science-backed psychedelic wellness sector, Delic has transformed itself into a sprawling conglomerate with services spanning all areas within the sector. The company’s related businesses now include trusted media and e-commerce platforms like Reality Sandwich and Delic Radio; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and Ketamine Infusion Centers and Ketamine Wellness Centers (pending acquisition), making it the largest psychedelic wellness clinic chain in the country. According to the National Institute of Mental Health, over 17 million Americans have at least one major depressive episode every year, and up to 30 percent of them receive insufficient help from current medical treatments. Meanwhile, a further estimated 40 million adults struggle with anxiety disorders. In a move towards addressing the growing health crisis in 2018, the FDA moved towards granting psilocybin “breakthrough therapy” status for the treatment of severe depression. Shortly thereafter, first Denver and then Oakland voted to decriminalize the use of psilocybin mushrooms, with the state of California currently reviewing a bill to decriminalize a wide variety of psychedelics (https://ibn.fm/SV0LT). With the sector on the cusp of broad-based legalization, the psychedelic drugs market is now projected to grow to a size of $10.75 billion by 2027, up from $4.75 billion in 2020 with a forecast CAGR of 12.36 percent over the period of 2021-2027 (https://ibn.fm/sqQwO). Delic has responded by servicing the growing interest within the sector through the expansion of its wide-ranging media business, which includes the provision of a free education platform; hosting Meet Delic, the first-ever psychedelic wellness summit; and the creation of Delic Radio — a station featuring over 43 podcast episodes delving into different aspects of the psychedelic industry. Simultaneously and in line with their goal of enabling billions of people to live happier lives through the provision of psychedelic treatments, Delic has acquired Ketamine Infusion Centers, which operates two ketamine clinics located in Bakersfield, California, and Phoenix, Arizona, and recently announced its acquisition of Ketamine Wellness Centers, which currently operates 10 clinics across Arizona, Colorado, Florida, Illinois, Minnesota, Nevada, Texas and Washington. Delic expects to open 15 additional clinics across the country over the next 18 months. In recognition of the rapidly changing state of the industry, Delic has also focused its efforts around Delic Labs, a licensed cannabis and psilocybin research laboratory. It is the only Health Canada-licensed entity to exclusively focus on research and development of psilocybin vaporization technology. The psychedelic wellness industry has long been recognized as one of the fastest growing segments within the global healthcare industry. With its business spanning all aspects of the sector, Delic looks optimally positioned to benefit from the continued growth in the sector and the ongoing legalization efforts around the world. For more information, visit the company’s website at www.DelicCorp.com. NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF

• Up to 50% of cancer is preventable, while other types can be detected or treated early, often resulting in complete remission for patients
• AnPac Bio-Medical Science Co., Ltd. uses blood-based testing to detect many types of cancer (multi-cancer tests) and pre-cancer diseases, predicting its potential to occur in the future
• Company’s proprietary CDA technology is powered by a database of over 220,000 clinical and general population test samples and cases and leverages a proprietary algorithm to generate personalized cancer screening
• Its follow-up study on multi-cancer risk assessment tests is believed to be the largest on-going study which has demonstrated its effectiveness with significant amount of confirmed cases of over 20 cancer types, over 20 pre-cancer diseases and major diseases at the hospitals

Cancer is the second leading cause of death worldwide, claiming approximately 10 million lives per year, which equals approximately one in six of all annual deaths. With the proper screening and detection methods, as well as healthy lifestyle choices including public health measures like immunizations against infections that could cause cancer, the World Health Organization (“WHO”) estimates that up to 50% of cancers could be prevented. Many of the cancers that are not preventable can be detected early, treated, and cured – sending the patient into remission (https://ibn.fm/sYvxk). But cancers are frequently not caught by general practitioners, missed because the symptoms are overlooked or attributed to something else. The results can be deadly, with cancers being detected at a dangerously late stage. AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company focused on cancer screening and early detection, has developed a proprietary approach to detect cancerous and pre-cancerous diseases – Cancer Differentiation Analysis (“CDA”) technology. CDA uses the blood’s natural biophysical properties to identify cancerous environments before tumors even form. CDA platform, in which CDA technology is combined with protein based biomarker tests to obtain even more comprehensive information, can be used to obtain more comprehensive data and information. Unlike most liquid-based cancer screening and detection methods, CDA platform from AnPac Bio focuses on assessing the existing protein based biomarkers with biophysical properties of the blood tested to signal the lead-up to serious health problems, including cancer, which has been used to help assessing cancer risk and its type, and predict where the risk is highest in the future through a standard blood test. CDA is powered by a database of over 220,000 samples and cases, allowing it to serve as a new approach to disease and cancer screening. AnPac Bio’s technology leverages a proprietary algorithm that synthesizes the data, effectively generating a personalized assessment approach for general population. Through CDA and CDA platform, AnPac Bio aims to fulfill numerous goals, including:

• Innovate: In the cancer screening industry, AnPac Bio is an innovator. CDA research has been ongoing since 2008, with commercial operations commencing in 2015. The company considers itself a thought leader in developing multi-cancer screening
• Detect: AnPac Bio is passionate about the early detection of signals of life-threatening cancers
• Identify: AnPac Bio’s CDA identifies the risks of up to 26 different types of cancers with high sensitivity and specificity
• Provide: AnPac Bio’s platform provides a multi-level and multi-parameter analysis with proprietary algorithmic assessment, resulting in accurate and easy-to-understand results
• Prove: Using the analysis of database consisting of over 220,000 samples, AnPac Bio and its CDA technology have been proven to identify individuals with pre- and early-stage cancer in general population that were previously assessed “cancer-free” through more conventional testing methods
• Biophysical Properties: CDA focuses on analyzing biophysical properties of human blood samples and correlates them to biophysical properties and cancer occurrence

AnPac Bio is thus uniquely positioned to disrupt the global cancer diagnostics market, which is expected to reach $249.6 billion by 2026, growing at a CAGR of 7% during the forecast period (https://ibn.fm/0Nt7e). The rapid growth in the industry can be attributed to the increased need for early detection and screening methods, which AnPac Bio and its proprietary technology offer. For more information, visit the company’s website at www.AnPacBio.com. NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

• Cannabis-delivery acquisitions increasing as companies want in on explosive growth of e-commerce cannabis sales
• CEO announces newly acquired property will serve as location of new SGMD Nug Avenue delivery hub
• Sugarmade signed MOU for licenses to serve as essential piece of plan to open three cannabis-related commercial operations in California

Amid growing interest and acquisition activity in California’s direct-to-consumer cannabis delivery sector, Sugarmade (OTC: SGMD) has closed on its most recent acquisition, a parcel of prime property in Los Angeles, which it plans to use as a new distribution/delivery hub for its Nug Avenue cannabis delivery segment (https://ibn.fm/4jB0F). “The explosive growth of e-commerce during the COVID-19 pandemic has propelled new interest in acquisitions involving direct-to-consumer cannabis delivery,” reported a recent MJBizDaily article (https://ibn.fm/XCG1q). “Some marijuana companies have acquired delivery-only cannabis dispensaries, while others have spent more to acquire vertically integrated MJ firms with home-delivery operations included. The article noted that companies involved in recent delivery-related acquisitions have said that the deals help them quickly access an existing base of loyal delivery customers, gain delivery expertise to apply to their existing operations and leverage delivery assets in other U.S. markets. “I think these M&A transactions are a part of a bigger phenomenon, which is the growth of delivery. It’s one way to achieve that – you acquire it,” the article quoted investment banker Frank Columbo as saying. Columbo is director of data analytics at Viridian Capital Advisors, which tracks capital raises, mergers and acquisitions in the cannabis sector. “We are very excited to announce the upcoming location of our new Nug Avenue delivery hub, which is in a prime position to serve the downtown LA area,” said Sugarmade CEO Jimmy Chan. “Our initial Nug Avenue location has been open for nearly six months and has established a strong brand with tremendous growth in membership — already exceeding 10,000 members and growing fast. Our remaining licenses can be applied to both expansion and verticalization of Nug Avenue operations as we continue to build a top-tier, farm-to-door leader in the California cannabis marketplace.” Prior to closing on the acquisition of the LA property, Sugarmade signed a memorandum of understanding to obtain three nonstorefront California cannabis licenses from the Los Angeles Department of Cannabis Regulation, along with corresponding licenses from the California Bureau of Cannabis Control. Combined, these licenses provide an essential piece of SGMD’s strategic plan to open three new cannabis-related commercial operations in California. According to the announcement, the Company intends to use one of the licenses, once obtained, to this newly acquired property in LA; the company will designate it as a licensed cannabis delivery business under its Nug Avenue brand. Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes Nug Avenue, CarryOutsupplies.com, SugarRush(TM), Lemon Glow and BudCars. For more information, visit the company’s website at www.Sugarmade.com. NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SGMD